

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Atrial fibrillation and female sex

This is a pre print version of the following article:

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1548772> since 2016-06-19T09:50:56Z

Published version:

DOI:10.2459/JCM.0000000000000239

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)



UNIVERSITÀ DEGLI STUDI DI TORINO

This is an author version of the contribution published on:

Questa è la versione dell'autore dell'opera:

Journal of cardiovascular medicine, 16(12), 2015, 10.2459/JCM.000000000000239

The definitive version is available at:

La versione definitiva è disponibile alla URL:

http://journals.lww.com/jcardiovascularmedicine/Abstract/2015/12000/Atrial_fibrillation_and_female_sex.1.aspx

Atrial Fibrillation and Female gender

*Anselmino Matteo MD, *Battaglia Alberto MD, *Gallo Cristina MD, *Gili Sebastiano MD,
*Matta Mario MD, *Castagno Davide MD, *Ferraris Federico MD, *Giustetto Carla MD,
*Gaita Fiorenzo MD

* Division of Cardiology, Department of Medical Sciences, Città della Salute e della Scienza, University of Turin, Italy

Corresponding author: Fiorenzo Gaita, MD Professor,

Cardiology Division, Città della Salute e della Scienza, University of Turin;

Corso Dogliotti 14, 10126 Turin, Italy

tel. 011.633.6767 - 6768 – 6763 – 6023 fax 011.633.6769

Email: fiorenzo.gaita@unito.it

Key-words: Atrial fibrillation, Gender related differences, Thromboembolic risk,
Transcatheter ablation.

Word count: 3215 words, 1 table, 3 figures, 59 references

Abstract

Atrial Fibrillation (AF) is the most common supraventricular arrhythmia. Its prevalence increases with age and preferentially affects male patients. Over 75 years of age, however, being female patients more prevalent, the absolute number of patients affected is similar between genders. Despite this few data are available in literature concerning gender related differences in AF patients. The present systematic review therefore considers comorbidities, referring symptoms, quality of life, pharmacological approaches and transcatheter ablation in female rather than male AF patients in search of parameters that may impact on treatment outcome. In brief, female AF patients more commonly present comorbidities leading to an higher prevalence of persistent AF, moreover they refer to hospital care later and with a longer disease history. AF symptoms relate to low quality of life in female patients, in fact AF paroxysm usually present higher heart rate leading to preferentially adopt a rate rather than a rhythm control strategy. Female AF patients present an increased risk of stroke, worsened by the lower OAT prescription rate related to the concomitant higher haemorrhagic risk profile. Transcatheter ablation is under used in female patients and, on the other side, they are more commonly affected by antiarrhythmic drug side effects.

List of abbreviation

A&P, ablate and pace; AF, Atrial Fibrillation; AAD, antiarrhythmic drugs; CAD, coronary artery disease; CRT, cardiac resynchronization therapy; ECG, electrocardiogram; EF, ejection fraction; HF, heart failure; NOAC, new oral anticoagulant; OR, odd ratio; PVI, pulmonary vein isolation; RA, right atrium; SCI, silent cerebral ischemia; TC, transcatheter; TE, thromboembolic.

Introduction

Atrial fibrillation (AF) is the most common supraventricular arrhythmia and, given the progressive ageing of the population, its prevalence is expected to increase. That AF represents a relevant topic is proved by the high number of publications produced every year, however few female patients are included in the available clinical randomized trials and guidelines ^{1, 2, 3} do not specifically address this subgroups of patients ^{4, 5}. We therefore performed the present systematic literature review on AF gender related differences to highlight characteristics, AF related risk, therapeutic strategies and outcomes in female suffering AF.

Epidemiology

Atrial Fibrillation prevalence increases with ageing ⁶, with 50% of AF patients having more than 75 years⁷. Atrial fibrillation can represent an epiphenomena of an underlying structural cardiomyopathy but can also occur in patients without any structural heart disease (known as Lone AF). The Framingham Heart Study ⁸, a population based prospective study on 8725 pts monitored, between 1968 and 1999, the life time risk of AF onset. At 40 years of age the AF onset risk for both genders was 1 in 4. Considering patients without history of heart failure (HF) or ischemic cardiomyopathy (CAD), AF onset risk decreased to 1 in 6. In the Copenhagen City Heart Study ⁹, instead, considering patients aged 50-89 years, during a period from 1976 to 1994, male sex related to a more than 2 fold AF prevalence increase.

Gender related differences in patients referring for AF.

Comorbidities. Several studies have reported gender related differences, concerning clinical characteristics, in patients referring for AF, but overall female prevalence in each study is low (mean female gender prevalence around 33%). In the AFFIRM study ¹⁰ (Atrial Fibrillation Follow-up Investigation of Rhythm Management), a prospective study based on 2033 patients, female patients were significantly older (71.8 yrs vs 68.4 yrs, p value < 0.001) with a greater prevalence of valvular cardiomyopathy (p value < 0.001). On the other side male gender was preferentially associated with CAD and HF (both p value < 0.001). In the CARAF study ¹¹ (Canadian Registry of Atrial Fibrillation), a prospective study based on 899 patients aiming to evaluate long-term AF progression rate, arterial hypertension and disthyroidism were preferentially observed in female patients. In the RACE study ¹² (Rate Control versus Electrical Cardioversion), a prospective randomized study based on a sample size of 522 patients, female patients were preferentially older (71 yrs vs 67 yrs, p value < 0.001) with a greater prevalence of hypertension and diabetes (both p value < 0.001) and similar results were disclosed in other retrospective studies ^{13, 14, 15}. Considering the Euro Heart Survey on Atrial Fibrillation ¹⁶, a multicentric study based on 5333 AF patients, female patients were older (70 yrs vs 64 yrs, p value < 0.001) with a greater prevalence of diabetes, hypertension, disthyroidism and valvular cardiomyopathy (p value < 0.001). Eventually a recent survey involving 3119 AF patients ¹⁷ (40% female), confirmed female gender patients were older, with an higher hypertension prevalence (p value < 0,001) and with an higher prevalence of valvular cardiomyopathies.

The explanation of why female AF patients present more comorbidities is not clear most likely is the results of multiple factors. An attitude to seek for medical advice later compared to males, finally presenting with longer arrhythmia history, may play a role. On the other side the higher prevalence of cardiomyopathies reported in female patients is surely related to the

older age of this subgroups of patients anyhow evidently more affected from degenerative valvulopathies (e.g. rheumatic) than males. Eventually the hormonal asset plays an important role^{18, 19}. While estrogen receptors in the cardiac tissue have shown to slow right atrium (RA) conduction and prolong RA refractoriness²⁰, Progesterone seems to oppose these effects²¹. In fact, higher arrhythmia occurrence has been reported in the luteal phase of the menstrual cycle^{22, 23} and several balances may be expected to change in menopause. Table 1 summarizes main gender related differences in AF patients. The evident greater comorbidities background present in female AF patients, in fact, leads to an increased arrhythmia burden determining a greater proportion of persistent/permanent AF compared to the male counterpart^{14,15}.

Symptoms and quality of life. Paquette et al¹³ reported that, at referral, female gender was related to a lower quality of life due to higher severity of AF symptoms. Similar results are reported in the study by Lip et al¹⁷. By consequence the rhythm control strategy proposed, determined a significant improvement, measured by the Physical Health (SF36) questionnaire, especially within female patients. One main reason of the impact of symptoms in females is the higher atrio-ventricular penetrance of the arrhythmia, leading to the faster ventricular heart rate during paroxysms, compared to males^{11,24}. The Canadian Trial of Atrial Fibrillation²⁵ reported that on a sample size of 234 patients (41% female), female gender was associated with worst functional capacity (DASI score, p value < 0.01), physical performance (SF36, p value < 0.01) and symptoms burden (frequency, p value < 0.01; severity, p value = 0.04). Also in this study rhythm control strategy, achieving a reduction of AF paroxysms, brought to quality of life improvement already after three months of treatment.

Within the factors influencing quality of life perception of AF female patients, surely anxiety/depression need to be taken into account²⁶. Based on available studies it cannot be excluded that gender related differences concerning QoL perception may relate to higher

sensitivity toward the disease and/or to a different perception of the illness. In fact, female patients do have higher tendency to somatization ²⁷, suggesting that, at least part of the gender related differences, may be of psychosomatic nature.

Thromboembolic and hemorrhagic risk profile. Female gender is associated to a greater AF related thromboembolic (TE) risk. In fact, since the study by Wolf et al ²⁸ demonstrated that TE events were significantly higher in female than in male AF patients (25% vs. 10%) female gender has been included in the Framingham stroke risk scheme ²⁹ and in another contemporary prognostic score ³⁰. A greater TE event rate in female patients was reported, in addition, in The Euro Heart Survey on Atrial Fibrillation ¹⁶ (odds ratio 1.83, p value = 0.019). In The ATRIA study ³¹, a prospective multicenter study on 17974 pts, after removing other TE risk factors (age, previous stroke, hypertension, HF, CAD, diabetes and estrogens replacement therapy), without assuming oral anticoagulants (OAT), female gender related to a greater TE event rate (3.5% vs. 1.8%; relative risk= 1.6; Figure 1).

Based on these evidences Lip et al ³² proposed the Birmingham 2009 scheme (acronym CHA₂DS₂-VASc) in which female gender was considered, for the first time, an independent stroke risk factor for AF patients. Many recent studies ³³ and meta-analysis ³⁴ have confirmed this theory and have added that the risk is enhanced in older female patients ³⁵ and despite similar levels of anticoagulation ³⁶. Unfortunately the increased TE risk is also associated with an higher mortality ³⁷. To date, the only limit is that these conclusions are based on clinical trials involving preferentially patients from western countries. Experiences in eastern countries did not lead to similar results. Inoue H et al ³⁸, followed for 2 years 7406 Japanese patients (29% female gender) appropriately treated with OAT without reporting an increased TE risk within females. Symptomatic TE events may however not best represent the risk. Vermeer et al ³⁹ reported that, based on a sample size of 1077 patients undergoing cerebral

MR, female gender was an independent risk factor also for silent cerebral ischemia (SCI; OR 1.4) known to be related with cognitive decline⁴⁰. In the Rotterdam study⁴¹, in fact, based on a large sample size of 6584 patients aged between 55 and 106 years, AF was significantly related both to dementia (OR 2.3) and cognitive impairment (OR 1.7).

As further discussed in the next session (see Oral Anticoagulant therapy) the increased stroke risk observed in female patients is worsened by the lower OAT prescription rate, most likely due to the concomitant higher haemorrhagic risk profile. In the CARAF study¹¹, based on 899 patients (37.7 % female) the mean INR observed at the time of an haemorrhagic event was above the normal range in both genders: 4.02 in female pts, 4.37 in male pts (p value 0.787). However female gender was associated with an increased hemorrhagic risk related to OAT (9.2% vs 2.8%; RR 5.49) with female patients treated with OAT having a more than 3 fold increased risk of a major hemorrhagic event compared to males (Figure 1). Similar results are reported in the SPORTIF trial⁴².

AF management

Oral anticoagulant therapy. Despite female gender represents an independent stroke risk factor, female patients are not properly prescribed OAT. Majeed et al⁴³ based on 1.4 million UK patients reported a lower OAT prescription rate in female (25% vs 34%) than male patients. Similar conclusions are reported in a prospective study based on a sample size of 228 AF patients⁴⁴. In this study OAT eligibility, considering the SPAF 3 score, was confirmed in 41% of the patients, but between these only 23% were properly treated by OAT. Moreover OAT was preferentially prescribed in male patients aged between 65 and 74 years (41%), on the other side female patients aged more than 75 years old were less prescribed OAT (12%). In the CARAF study¹¹ female patients aged more than 75 years old were preferentially

prescribed Acetylsalicylic acid rather than OAT; in fact considering elderly AF patients with ≥ 1 stroke risk factor OAT was more commonly prescribed in male than in female patients (44.9% vs. 24.5%, p value = 0.034). More recently, in The Euro Heart Survey study ¹⁶, at least at discharge, OAT was equally proposed to male rather than female patients (65% vs 65%, p value NS) and the situation was similar within 7406 Japanese patients ³⁸. Eventually, however, a large sample size study reported a lower OAT prescription rate in female patients rather than the male counterpart (76.2 and 95.3% respectively, $P < 0.001$)¹⁷.

Concerning new oral anticoagulant (NOAC) ^{45, 46, 47, 48} instead, while with dabigatran the annual absolute risk reduction was similar between male and female, with apixaban there was a trend to lower risk of major bleeding among females ($p=0.08$).

Pharmacological therapy and transcatheter ablation. Unfortunately few studies report if AF management is influenced by gender. Exhaustive data are reported solely in The Euro Heart Survey study ¹⁶ in which, female patients presented greater AF burden and higher heart rate during AF paroxysms. In this Survey, in case of referral for typical symptoms (for instance syncope or irregular heartbeat) no gender related differences in AF management emerged. In case of atypical symptom presentation, or in asymptomatic patients, instead, female patients were treated less aggressively and most often by rate control strategy (Figure 2). Similar results are reported in a recent study by Salam et al ⁴⁹ in which, based on a large series of patients (n 3849, females 36.8%) from Middle East, female AF patients were preferentially treated, at discharge, with digoxin and calcium channel blockers for rate control strategy.

In case rhythm control strategy by antiarrhythmic drugs (AAD) fails and AF remains symptomatic a further option is transcatheter (TC) AF ablation ⁵⁰. Also in this respect, few

studies have focused on gender related differences. The study by Forleo et al ¹⁴ underlines how female patients referring for TC AF ablation, not only present more comorbidities, but also have a longer AF history (60 vs. 47 months, p value = 0.04), significantly larger left atriums (AP diameter 44 mm vs. 40 mm, p value = 0.003) and lower prevalence of Paroxysmal AF (56.3 vs. 61.3, p value NS). In a study by Patel et al ¹⁵ female patients referred for AF TC ablation were significantly older (59 ± 13 vs. 56 ± 19 years; p value <0.01), with a lower prevalence of Paroxysmal AF (46% vs. 55%; p value <0.001), with a greater number of previous ineffective AAD (4 ± 1 vs. 2 ± 3 ; p value = 0.04) and a longer AF history (6.51 ± 7 vs. 4.85 ± 6.5 years; p value = 0.02) than males. In addition female patients underwent also a greater number of failed AF ablation procedures (31.5% vs. 22.5%; p value < 0.001). Recently Zhang et al ⁵¹, considering a sample size of 200 patients (33% female) undergoing AF TC ablation reported how Lone AF was less frequently observed in female patients (27.4% vs 47.6%; p value = 0.004).

Outcome

In the RACE study 8522 patients have been enrolled and prospectively randomized to rate or rhythm control to evaluate long-term outcome and safety gender related differences. Female patients enrolled in the rhythm control strategy reported a higher incidence of HF, TE events and AAD related adverse events (p value = 0.002) in comparison to female patients enrolled in the rate control strategy.

More specifically concerning rhythm control strategies Essebag et al ⁵² have enrolled 1005 patients with new onset AF to evaluate safety and efficacy of long-term therapy with Amiodarone. In this study bradycardia induced by Amiodarone was more pronounced in

female patients (HR, 4.69; vs. HR, 1.05; p value = 0.02) even excluding confounding factors such as body weight, BMI, Amiodarone daily dosage and assumption of other drugs (both for rhythm or rate control strategies). In fact, gender related differences on efficacy of AAD are also reported in the CARAF study¹¹ in which arrhythmia recurrence rate was higher in female patients (p value < 0.05 for ecg documented recurrences, p value < 0.001 for non documented recurrences). However, despite a higher arrhythmic burden in female patients the progression rate to permanent AF was identical between genders (18.9%), so as the mean time of progression (1092 days vs 1138 days, p value = 0.35).

Concerning AF TC ablation, instead, Forleo et al¹⁴ failed to report any safety and efficacy gender related difference. Periprocedural complication rate was 5.0%, similar between genders. In this study aim of radiofrequency ablation was complete pulmonary vein isolation (PVI); cavo-tricuspid isthmus block was also pursued in each procedure, but left atria linear lesion were performed according to the operator discretion. After a median follow up of 22.5 ± 11.8 months the proportion of patients arrhythmia free was similar (83.1 vs. 82.7% female vs. male patients), and similar results were reported also for quality of life were only a slightly superior improvement occurred in female patients (p value < 0.05 in comparison to baseline in both genders). Differently Patel et al¹⁵ reported that female gender was associated with periprocedural hemorrhagic complications, in particular, greater hematoma (2.1% vs. 0.9%; p value = 0.026) and pseudoaneurism incidence (0.6% vs. 0.1%; p value = 0.031) in comparison with male patients. In this study PVI for paroxysmal and PVI + atrial linear lesions + complex fractionated atrial electrograms (CFAE) for persistent AF patients were performed. After a median follow up of 24 ± 16 months, female patients were affected by an higher recurrence rate with a lower percentage of arrhythmia free survival (68.5% vs. 77.5% p value < 0.001). Female gender was associated with an higher rate of periprocedural complications, in

particular vascular complications. A similar finding was, in fact, reported also in a single centre retrospective study on 1295 patients by Baman et al⁵³. In addition recently Zhang et al⁵¹, on a small cohort of 220 patients (33.2% females), reported an higher periprocedural vascular complication rate in female patients (6.8% vs 0.7%, p value 0.027). In this study ablation procedure was performed with the aim to complete PVI and linear lesions plus CFAE were pursued and ablated in case of persistent AF. Female gender resulted an independent risk factor for AF recurrences following AF ablation (mean follow up time 19 ± 5 months, 35.6% vs 57.1%; p value = 0.003, HR 1.663, CI 1.114 – 2.485; p value = 0.013). Eventually, as for Forleo et al¹⁴, Takigawa et al⁵⁴, considering a large sample size study (n 1124 patients, 23.1% female), reported that female gender was not associated with an higher periprocedural complication rate (p value = 0.73) and neither with a lower efficacy following the first AF ablation procedure (mean follow up time 31.7 ± 24.4 months, 56.4% vs. 59.3% at 5 years, p value = 0.24). A lower efficacy rate was reported, instead, in female patients undergoing a redo procedure (mean follow up time 39.0 ± 21.8 months, 76.5% vs. 81.3% at 5 years, p value = 0.007). Despite an ablation protocol aiming to PVI in all patients and atrial linear ablations if required (spontaneous AF from undetermined origins or atrial tachycardia). Eventually obesity has shown to increase periprocedural complication rate especially in female gender patients⁵⁵. Indeed to afore described studies are heterogeneous and the outcome reported is surely influenced by differences in baseline characteristics. When female patients presented more comorbidities (e.g. Patel et al¹⁵) AF TC ablation's outcome was worst while when baseline characteristics were comparable to those of enrolled males (e.g. Takigawa et al⁵⁴) outcome did not differ. Therefore, differently from AAD, there are to date no reasons to support an inter-gender outcome difference following AF ablation given similar baseline comorbidities and stage of the disease^{56, 57}. In fact, a recent investigation has shown no systematic between gender differences in PV or atrial substrate when stratified by

cardiovascular comorbidities known to be associated with atrial remodelling ⁵⁸. In our opinion, therefore, the most important discriminating factor remains the timing of the therapeutic intervention aiming towards rhythm control.

Eventually concerning device therapy, ablate and pace (A&P) followed by a cardiac resynchronization therapy (CRT) should be adopted in all patient with uncontrolled heart rate with reduced ejection fraction (EF) and any QRS duration (Class IIa, Level B) ⁵⁹; however no specific gender related differences have been reported on this approach.

In general, however, a multicenter registry focusing on AF management in females is warranted.

Conclusion.

Atrial fibrillation is the most common sustained supraventricular arrhythmia. Its onset is age and sex related, in fact, elderly people and males are preferentially involved. Despite this, considering that beyond 75 years of age females are more prevalent, the absolute number of patients affected in this age frame are similar between genders. Despite this few data are available in literature concerning gender related differences in AF patients.

Based on the present systematic review the following observations deserve, in our opinion, attention from the medical community (Figure 3).

- Female patients represents about one third of patients enrolled in available studies and generally present more comorbidities.

- Female AF patients present a lower quality of life and referral to hospital care occurs later and with a longer disease history. This commonly leads to preferentially adopt a rate rather than a rhythm control strategy, while the latter, by reducing the arrhythmic burden, has proved to more significantly improve quality of life in female vs. male patients.
- Female AF patients present an increased risk of stroke, worsened by the lower OAT prescription rate related to the concomitant higher haemorrhagic risk profile.
- Rhythm control strategy pursued by pharmacological therapy is associated with an higher risk of adverse events, and, may be affected by lower efficacy on the long-term follow up. On the other side AF TC ablation is under prescribed in female patients and, in particular, females are referred later, with greater comorbidities and longer AF history.

Acknowledgments

None to declare

Funding

None to declare

Disclosure

None to declare

References

- ¹ January CT, Wann LS, Alpert JS et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *Circulation*. 2014 Apr 10. [Epub ahead of print] PubMed PMID: 24682347.
- ² European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). *Eur Heart J*. 2010 Oct;31(19):2369-429.
- ³ Camm AJ, Lip GY, De Caterina R et al; ESC Committee for Practice Guidelines-CPG; Document Reviewers. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. *Europace*. 2012 Oct;14(10):1385-413.
- ⁴ Cappato R, Calkins H, Chen SA et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. *Circ Arrhythm Electrophysiol*. 2010 Feb;3(1):32-8.
- ⁵ Devlin G. Women and elderly: subgroups under-represented in clinical trials. *Curr Opin Cardiol* 2010(25):335–339
- ⁶ Michael W. Rich. Epidemiology of atrial fibrillation. *J Interv Card Electrophysiol* (2009) 25:3–8
- ⁷ Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. *Am J Cardiol* 2009;104:1534–1539.
- ⁸ Lloyd-Jones DM, Wang TJ, Leip EP et al. Lifetime Risk for Development of Atrial Fibrillation The Framingham Heart Study. *Circulation*. 2004;110:1042-1046.
- ⁹ Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Sex-Specific Increase in the Prevalence of Atrial Fibrillation (The Copenhagen City Heart Study) *Arch Intern Med*. 1995 Mar 13;155(5):469-73
- ¹⁰ Kaufman ES, Zimmermann PA, Wang T et al; Atrial Fibrillation Follow-up Investigation of Rhythm Management investigators. Risk of proarrhythmic events in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study: A multivariate analysis. *J Am Coll Cardiol*. 2004;44:1276–1282.
- ¹¹ Humphries KH, Kerr CR, Connolly SJ et al. New-Onset Atrial Fibrillation Sex Differences in Presentation, Treatment, and Outcome. *Circulation*. 2001;103:2365-2370.
- ¹² Rienstra M, Van Veldhuisen DJ, Hagens VE et al; RACE Investigators. Gender-Related Differences in Rhythm Control Treatment in Persistent Atrial Fibrillation. *J Am Coll Cardiol* 2005;46:1298 –306.
- ¹³ Paquette M, Roy D, Talajic M et al. Role of Gender and Personality on Quality-of-Life Impairment in Intermittent Atrial Fibrillation. *Am J Cardiol* 2000;86:764–768.
- ¹⁴ Forleo GB, Tondo C, De Luca L et al. Gender-related differences in catheter ablation of atrial fibrillation. *Europace* (2007) 9, 613–620.
- ¹⁵ Patel D, Mohanty P, Di Biase L, Sanchez JE et al Outcomes and complications of catheter ablation for atrial fibrillation in females. *Heart Rhythm* 2010;7:167–172
- ¹⁶ Dagres N, Nieuwlaat R, Vardas PE et al. Gender-Related Differences in Presentation, Treatment, and Outcome of Patients With Atrial Fibrillation in Europe A Report From the Euro Heart Survey on Atrial Fibrillation. *J Am Coll Cardiol* 2007;49:572–7.
- ¹⁷ Lip GY, Laroche C, Boriani G et al. Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot survey on Atrial Fibrillation. *Europace*. 2014 Jun 22. pii: euu155. [Epub ahead of print]

-
- ¹⁸ Stumpf WE, Sar M, Aumüller G. The heart: a target organ for estradiol. *Science*. 1977 Apr 15;196(4287):319-21.
- ¹⁹ McGill HC Jr, Anselmo VC, Buchanan JM, Sheridan PJ. The heart is a target organ for androgen. *Science*. 1980 Feb 15;207(4432):775-7.
- ²⁰ Rosano GM, Leonardo F, Dicandia C et al: Acute electrophysiologic effect of estradiol 17 β in menopausal women. *Am J Cardiol* 2000;86:1385-1387.
- ²¹ Nakamura H, Kurokawa J, Bai C-X et al: Progesterone regulates cardiac repolarization through a nongenomic pathway: An in vitro patch clamp and computational modeling study. *Circulation* 2007;116:2913- 2922.
- ²² Rosano GM, Leonardo F, Sarrel PM, Beale CM, De Luca F, Collins P: Cyclical variation in paroxysmal supraventricular tachycardia in women. *Lancet* 1996;347:786-788.
- ²³ Myerburg RJ, Cox MM, Interian A et al: Cycling of inducibility of paroxysmal supraventricular tachycardia in women and its implications for timing of electrophysiologic procedures. *Am J Cardiol* 1999;83:1049-1054.
- ²⁴ Hnatkova K, Waktare JE, Murgatroyd FD, Guo X, Camm AJ, Malik M. Age and gender influences on rate and duration of paroxysmal atrial fibrillation. *Pacing Clin Electrophysiol*. 1998 Nov;21(11 Pt 2):2455-8.
- ²⁵ Dorian P, Paquette M, Newman D et al. Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. *Am Heart J* 2002;143:984-90
- ²⁶ Akintade BF, Chapa D, Friedmann E, Thomas SA. The Influence of Depression and Anxiety Symptoms on Health-Related Quality of Life in Patients With Atrial Fibrillation and Atrial Flutter. *J Cardiovasc Nurs*. 2013 Oct 24. [Epub ahead of print]
- ²⁷ Paquette M, Roy D, Talajic M et al. Role of Gender and Personality on Quality-of-Life Impairment in Intermittent Atrial Fibrillation. *Am J Cardiol* 2000;86:764–768.
- ²⁸ Wolf PA, Mitchell JB, Baker CS, Kannel WB, D'Agostino RB. Impact of atrial fibrillation on mortality, stroke, and medical costs. *Arch Intern Med*. 1998;158:229–234.
- ²⁹ Wang TJ, Massaro JM, Levy D et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community. The Framingham Heart Study. *JAMA* 2003;290:1049–56
- ³⁰ Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. *Stroke*. 1999 Jun;30(6):1223-9.
- ³¹ Fang MC, Singer DE, Chang Y et al. Gender Differences in the Risk of Ischemic Stroke and Peripheral Embolism in Atrial Fibrillation The Anticoagulation and Risk factors In Atrial fibrillation (ATRIA) Study. *Circulation*. 2005;112:1687-1691.
- ³² Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach The Euro Heart Survey on Atrial Fibrillation. *CHEST* 2010; 137(2):263–272.
- ³³ Friberg L, Benson L, Rosenqvist M, Lip GY. Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study. *BMJ*. 2012 May 30;344:e3522. doi: 10.1136/bmj.e3522
- ³⁴ Wagstaff AJ1, Overvad TF, Lip GY, Lane DA. Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis. *QJM*. 2014 Apr 9. [Epub ahead of print]
- ³⁵ Avgil Tsadok M, Jackevicius CA, Rahme E, Humphries KH, Behloul H, Pilote L. Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation. *JAMA*. 2012 May 9;307(18):1952-8.
- ³⁶ Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D. Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment. *Thromb Haemost*. 2009 May;101(5):938-42.

-
- ³⁷ Friberg J, Scharling H, Gadsbøll N, Truelsen T, Jensen GB; Copenhagen City Heart Study. Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study). *Am J Cardiol*. 2004 Oct 1;94(7):889-94.
- ³⁸ Inoue H, Atarashi H, Okumura K et al J-RHYTHM Registry Investigators. Impact of gender on the prognosis of patients with nonvalvular atrial fibrillation. *Am J Cardiol*. 2014 Mar 15;113(6):957-62.
- ³⁹ Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM. Prevalence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. *Stroke*. 2002 Jan;33(1):21-5.
- ⁴⁰ Gaita F, Corsinovi L, Anselmino M et al. Prevalence of silent cerebral ischemia in paroxysmal and persistent atrial fibrillation and correlation with cognitive function. *J Am Coll Cardiol*. 2013 Nov 19;62(21):1990-7.
- ⁴¹ Ott A, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE, Hofman A. Atrial Fibrillation and Dementia in a Population-Based Study The Rotterdam Study. *Stroke* 1997; 28: 316-321
- ⁴² Gombert-Maitland M, Wenger NK, Feyzi J et al. Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials. *European Heart Journal* (2006) 27, 1947–1953
- ⁴³ Majeed A, Moser K, Carroll K. Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994–1998: analysis of data from the general practice research database. *Heart* 2001;86:284–288
- ⁴⁴ Sudlow M, Thomson R, Thwaites B, Rodgers H, Kenny RA. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. *Lancet* 1998; 352: 1167–71
- ⁴⁵ Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2009; 361: 1139-1151.
- ⁴⁶ Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2011; 365: 981-992
- ⁴⁷ Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med* 2011; 365: 883-891.
- ⁴⁸ Shulman et al. New oral anticoagulant agents – general features and outcomes in subsets of patients. *Thromb Haemost* 2014; 111: 575–582.
- ⁴⁹ Salam AM, AlBinali HA, Al-Mulla AW et al. Women hospitalized with atrial fibrillation: Gender differences, trends and outcome from a 20-year registry in a middle eastern country (1991–2010). *Int J Cardiol*. 2013 Sep 30;168(2):975-80.
- ⁵⁰ Anselmino M, D'Ascenzo F, Amoroso G, Ferraris F, Gaita F. History of transcatheter atrial fibrillation ablation. *J Cardiovasc Med (Hagerstown)*. 2012 Jan;13(1):1-8.
- ⁵¹ Zhang XD, Tan HW, Gu J et al. Efficacy and Safety of Catheter Ablation for Long-Standing Persistent Atrial Fibrillation in Women. *Pacing Clin Electrophysiol*. 2013 Oct;36(10):1236-44.
- ⁵² Essebag V, Reynolds MR, Hadjis T et al. Sex Differences in the Relationship Between Amiodarone Use and the Need for Permanent Pacing in Patients With Atrial Fibrillation. *Arch Intern Med*. 2007;167(15):1648-1653
- ⁵³ Baman TS, Jongnarangsin K, Chugh A et al. Prevalence and Predictors of Complications of Radiofrequency Catheter Ablation for Atrial Fibrillation. *J Cardiovasc Electrophysiol*. 2011 Jun;22(6):626-31.
- ⁵⁴ Takigawa M, Kuwahara T, Takahashi A et al. Differences in catheter ablation of paroxysmal atrial fibrillation between males and female. *Int J Cardiol*. 2013 Oct 3;168(3):1984-91
- ⁵⁵ Shoemaker MB, Muhammad R, Farrell M, et al. Relation of morbid obesity and female gender to risk of procedural complications in patients undergoing atrial fibrillation ablation. *Am J Cardiol (United States)*, Feb 1 2013, 111(3) p368-73

⁵⁶ Scaglione M, Gallo C, Battaglia A et al. Long-term progression from paroxysmal to permanent atrial fibrillation following transcatheter ablation in a large single-center experience. *Heart Rhythm*. 2014 May;11(5):777-82.

⁵⁷ Santangeli P, di Biase L, Pelargonio G, Natale A. Outcome of invasive electrophysiological procedures and gender: are males and females the same? *J Cardiovasc Electrophysiol*. 2011 May;22(5):605-12.

⁵⁸ Walters TE, Teh AW, Spence S, Morton JB, Kistler PM, Kalman JM. Absence of Gender-Based Differences in the Atrial and Pulmonary Vein Substrate: A Detailed Electroanatomic Mapping Study. *J Cardiovasc Electrophysiol*. 2014 Jun 5. doi: 10.1111/jce.12465. [Epub ahead of print]

⁵⁹ Brignole M, Auricchio A, Baron-Esquivias G et al 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). *Europace*. 2013 Aug;15(8):1070-118.

Figure Legends

Figure 1 Thromboembolic and haemorrhagic events stratified by gender in two large cohorts.[12, 52]

Figure 2 Atrial Fibrillation management stratified by gender and symptoms at referral in the Euro Heart Survey [25]

Figure 3 Main gender related AF differences

First author, year	Sample size (females, %)	Significant gender related differences	p value
Kaufman ES et al 2004	2033 (37.9 %)	Age (Older)	< 0.001
		Valvular cardiomyopathy	< 0.001
Humphries K et al 2001	899 (37.7%)	Age (Older)	< 0.001
		Hypertension	< 0.001
		Disthyroidism	< 0.03
Paquette et al 2000	170 (36.5%)	Age (Older)	< 0.05
		Hypertension	< 0.05
Rienstra M et al 2005	522 (36.8%)	Age (Older)	< 0.001
		Hypertension	< 0.001
		Diabetes	< 0.001
Forleo et al 2007	221 (32.1%)	Age (Older)	= 0.002
		Hypertension	= 0.04
Patel D. et al 2010	3265 (15.8%)	Age (Older)	< 0.01
		Diabetes	0.016
		Hypertension	< 0.001
		Previous stroke	< 0.001
Dagres N et al 2007	5333 (42%)	Age (Older)	< 0.001
		Hypertension	< 0.001
		Diabetes	< 0.001
		Valvular cardiomyopathy	< 0.001
		Disthyroidism	< 0.001

Table 1 Main Gender related differences of patients referring for Atrial Fibrillation.

Figure 1
Click here to download high resolution image




Figure 2
Click here to download high resolution image




Figure 3
Click here to download high resolution image

